Allurion Technologies, Inc. (ALUR) Reports Q2 Loss, Misses Revenue Estimates

Allurion Technologies, Inc. (ALUR) reported a Q2 2025 loss of $0.57 per share, which was narrower than the $0.65 loss expected, but its revenue of $3.38 million significantly missed the Zacks Consensus Estimate by 43.21% and declined sharply from $11.77 million year-ago. This marks the fourth consecutive quarter Allurion has failed to meet revenue expectations, contributing to a 78% year-to-date stock decline. Consequently, unfavorable estimate revisions have led to a Zacks Rank #4 (Sell) rating, signaling anticipated near-term underperformance.

Analysis

Allurion Technologies (ALUR) reported highly concerning Q2 2025 results, characterized by a severe contraction in its top line. While the company posted a narrower-than-expected loss of $0.57 per share, beating the consensus estimate by 12.31%, this positive earnings surprise is eclipsed by a dramatic deterioration from the $0.25 earnings per share recorded in the prior-year quarter. The most alarming signal is the revenue performance, which came in at just $3.38 million, missing consensus estimates by a substantial 43.21% and collapsing from $11.77 million year-over-year. This marks the fourth consecutive quarter Allurion has failed to meet revenue expectations, indicating a persistent and deepening issue with its commercial execution or market demand. This operational failure is reflected in the stock's severe underperformance, having lost approximately 78% of its value year-to-date against a 9.7% gain in the S&P 500. The pre-existing unfavorable trend in estimate revisions has culminated in a Zacks Rank #4 (Sell), signaling continued near-term underperformance until management can provide a credible path to reversing these trends.

Key Decisions for Investors

• Investors should view the EPS beat with significant skepticism, as it is overshadowed by the catastrophic 71% year-over-year revenue decline and a 43% miss against consensus, which are more indicative of fundamental business health.
• Given the chronic revenue misses, severe stock underperformance, and a formal 'Sell' rating from Zacks, maintaining or initiating a long position appears high-risk until there is tangible evidence of a top-line turnaround.
• Pay close attention to management's commentary on the upcoming earnings call for specific details on the cause of the revenue collapse and any actionable recovery plan, as this will be the key determinant for any future re-evaluation of the stock's outlook.